# Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

> **NCT02047019** · PHASE3 · WITHDRAWN · sponsor: **Bayer**

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- **DRUG:** Candesartan Cilexetil
- **DRUG:** Candesartan matching placebo
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

## Key facts

- **NCT ID:** NCT02047019
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-01
- **Primary completion:** 2019-12-08
- **Final completion:** 2019-12-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** GPDC decided to terminate the study
- **Last updated:** 2017-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047019, "Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02047019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*